A 51-year-old man with a recurrent metastatic esthesioneuroblastoma (olfactory neuroblastoma) was referred for peptide receptor radionuclide therapy (PRRT). He received 4 treatments of 111In-octreotide over 8 months and 3 treatments of 177Lu-DOTATATE over 4 months, which helped alleviate his symptoms and improved his quality of life; however, the tumor ultimately progressed and he passed away shortly thereafter. PRRT with 111In-octreotide or 177Lu-DOTATATE could play a role in the management of esthesioneuroblastoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000000705 | DOI Listing |
Publication Analysis
Top Keywords
esthesioneuroblastoma olfactory
8
olfactory neuroblastoma
8
111in-octreotide 177lu-dotatate
8
neuroblastoma treated
4
treated 111in-octreotide
4
177lu-dotatate prrt
4
prrt 51-year-old
4
51-year-old man
4
man recurrent
4
recurrent metastatic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!